SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at two upcoming investor conferences:
- Cowen & Company 35th Annual Health Care Conference, The Boston Marriott Copley Place, Boston, March 4, 2015 at 10:40 a.m. ET.
- 27th Annual Roth Conference, Ritz Carlton Laguna Niguel, March 11, 2015 at 12:00 p.m. PT.
A live audio webcast of each presentation will be available through the Events and Presentations page of the company's corporate website (www.otonomy.com).
About Otonomy
Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information please visit www.otonomy.com.